What does Pharmapan do?

Pharmapan is a pharmacy in Schaarbeek. Private Limited, started on 27 May 2021, 1 establishment.

What is the address of Pharmapan?

The registered office of Pharmapan is located at Smaragdlaan 60, 1030 Schaarbeek.

Is Pharmapan still active?

Yes. According to the CBE (30 September 2026) Pharmapan is active, legal situation “Normale toestand”, started on 27 May 2021.

Is Pharmapan registered on Peppol?

No, Pharmapan is currently not registered on the Peppol network.

What is the enterprise number of Pharmapan?

The enterprise number of Pharmapan is BE0768826948.

When was Pharmapan founded?

Pharmapan was founded on 27 May 2021.

Who are the directors of Pharmapan?

According to the 2024 annual accounts, the directors of Pharmapan are: ZAKARIA BOUZID.

Is Pharmapan a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 May 2021; 4 annual accounts filed, latest fiscal year 2024; 1 directors known from the annual account.

How much profit did Pharmapan make in 2024?

Pharmapan recorded a loss after taxes of € 20,263 in financial year 2024.

What is the revenue of Pharmapan?

As a small company, Pharmapan is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € -21,138.

Pharmapan (Private Limited) - Schaarbeek - BE0768826948

Dossier Pharmapan, printed on 30 September 2026 from databakkes.be/en/0768826948/pharmapan. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2024

Pharmapan from Schaarbeek, company number BE0768826948, closed financial year 2024 with a result of € -20,263 after tax. For that financial year Pharmapan recorded a gross margin of € -21,138 and equity of € 131,175. Compared with financial year 2023, the result moved from € 26,496 to € -20,263. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 30, 2025.

What it is worth Healthy

€ 131,175

▼ 13% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -20,263

▼ still € 26,496 profit in 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 4,174

▼ 97% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 128,975.

People and assets in 2024

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Wage cost estimate Staff cost at a one-person company Staff Only people on the payroll count here.€ 34 Likely the director’s social contribution or pension premium.The director’s pay Already netted into the gross margin, not shown separately in the accounts. Typical for one-person companies € 45,000 gross per year minimum for the reduced tax rate≈ € 2,100 net per month after contributions, tax and usually some benefits in kind, roughly Assumption based on the chart of accounts, not a figure from the source.

€ 34

No payroll staff. An amount this small is usually a social contribution or pension premium for the director, booked under staff costs.

Vehicles and equipment

€ 2,336

▼ 38% vs 2023

Book value of vehicles, furniture and equipment.

Debts at end 2024

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 1,202

▼ 97% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 10,853

▼ 38% vs 2023

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Revenue	€ 69,400 Revenue 2021: € 69,400 First fiscal year in the series	-	-	-
Gross margin	€ 53,127 Gross margin 2021: € 53,127 First fiscal year in the series	€ 124,140 Gross margin 2022: € 124,140 ▲ 134% vs 2021 (€ 53,127) Favourable step	€ 38,187 Gross margin 2023: € 38,187 ▼ 69% vs 2022 (€ 124,140) Unfavourable step	€ -21,138 Gross margin 2024: € -21,138 ▼ € 59,325 vs 2023 (€ 38,187) Unfavourable step	▼ € 59,325
Profit after taxes	€ 38,257 Profit after taxes 2021: € 38,257 First fiscal year in the series	€ 84,486 Profit after taxes 2022: € 84,486 ▲ 121% vs 2021 (€ 38,257) Favourable step	€ 26,496 Profit after taxes 2023: € 26,496 ▼ 69% vs 2022 (€ 84,486) Unfavourable step	€ -20,263 Profit after taxes 2024: € -20,263 ▼ € 46,759 vs 2023 (€ 26,496) Unfavourable step	▼ € 46,759
Equity	€ 40,457 Equity 2021: € 40,457 First fiscal year in the series	€ 124,943 Equity 2022: € 124,943 ▲ 209% vs 2021 (€ 40,457) Favourable step	€ 151,438 Equity 2023: € 151,438 ▲ 21% vs 2022 (€ 124,943) Favourable step	€ 131,175 Equity 2024: € 131,175 ▼ 13% vs 2023 (€ 151,438) Unfavourable step	▼ 13%
Total debts	€ 16,190 Total debts 2021: € 16,190 First fiscal year in the series	€ 52,764 Total debts 2022: € 52,764 ▲ 226% vs 2021 (€ 16,190) Unfavourable step	€ 54,858 Total debts 2023: € 54,858 ▲ 4% vs 2022 (€ 52,764) Unfavourable step	€ 12,055 Total debts 2024: € 12,055 ▼ 78% vs 2023 (€ 54,858) Favourable step	▼ 78%
Cash	€ 19,729 Cash 2021: € 19,729 First fiscal year in the series	€ 134,015 Cash 2022: € 134,015 ▲ € 114,286 vs 2021 (€ 19,729) Favourable step	€ 153,874 Cash 2023: € 153,874 ▲ 15% vs 2022 (€ 134,015) Favourable step	€ 4,174 Cash 2024: € 4,174 ▼ 97% vs 2023 (€ 153,874) Unfavourable step	▼ 97%
Retained profit	€ 38,257 Retained profit 2021: € 38,257 First fiscal year in the series	€ 122,743 Retained profit 2022: € 122,743 ▲ 221% vs 2021 (€ 38,257) Favourable step	€ 149,238 Retained profit 2023: € 149,238 ▲ 22% vs 2022 (€ 122,743) Favourable step	€ 128,975 Retained profit 2024: € 128,975 ▼ 14% vs 2023 (€ 149,238) Unfavourable step	▼ 14%
Balance sheet total	€ 56,647 Balance sheet total 2021: € 56,647 First fiscal year in the series	€ 177,706 Balance sheet total 2022: € 177,706 ▲ 214% vs 2021 (€ 56,647) Unchanged	€ 206,297 Balance sheet total 2023: € 206,297 ▲ 16% vs 2022 (€ 177,706) Unchanged	€ 143,231 Balance sheet total 2024: € 143,231 ▼ 31% vs 2023 (€ 206,297) Unchanged	▼ 31%

Key figures of Pharmapan, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to Pharmapan?

What happened at Pharmapan in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 30, 2025 New annual accounts for financial year 2024: loss of € 20,263 (▼ € 46,759 vs 2023). filed late Source: NBB ↗
May 27, 2021 New establishment in Etterbeek. KBO
2021 ZAKARIA BOUZID became a director. NBB
May 27, 2021 Start of the company according to the CBE. KBO

In short

From € 38,257 profit in 2021 to € 20,263 loss in 2024.

Paid € 59,761 in corporate taxes since 2021.

Best year ever: 2022, with € 84,486 profit.

Original PDFs at the National Bank ↗

A new publication or filing at Pharmapan? We notify you, reason included.

Follow Pharmapan

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

ZAKARIA BOUZID

Pharmapan

Behind Pharmapan is ZAKARIA BOUZID.

See the full network in the app

Directors

According to the 2024 annual accounts

ZAKARIA BOUZID

Director

since 2021

Establishments

Establishment units

Physical locations of this company

Registered office

Smaragdlaan 60

1030 Schaarbeek

2.317.545.279

Peter Benoitstraat 37

1040 Etterbeek

Active since 27 May 2021

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

ALBROX

€ -308 gross margin · 2025

Association des copropriétaires de la résidence "Emeraude I" sis à 1030 Schaerbeek, avenue de l'Emeraude 60

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0768.826.948
VAT number: BE 0768.826.948
Registered office: Smaragdlaan 60, 1030 Schaarbeek
Names & denominations: Pharmapan
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 27 May 2021
Peppol: Not registered
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗